Craft

TaiRx

Stock Price

NT$30

2024-10-29

Market Capitalization

NT$3.2 B

2024-10-29

Revenue

NT$8.2 M

FY, 2024

TaiRx Summary

Company Summary

Overview
TaiRx (台睿生物科技股份有限公司) is a pharmaceutical company that focuses mainly on oncological research. Its product pipeline includes treatments for cancer, sepsis, colitis, and immune-related diseases. The company caters to the healthcare industry.
Type
Public
Status
Active
Founded
2011
HQ
Taipei, TW | view all locations
Website
https://www.trx.com.tw/en
Cybersecurity rating
Sectors

Key People

  • Yi-Wen Chu, Senior Vice President

    • Andrew Lin, Chairman

      • Sarah Lee, Director

        • Sheng-Chu Kuo, Director

          LocationsView all

          1 location detected

          • Taipei, New Taipei City HQ

            Taiwan

            6F-1, No.66, San-Chung Rd. Nankang Dist.

          TaiRx Financials

          Summary Financials

          Revenue (H1, 2025)
          NT$7.5M
          Gross profit (H1, 2025)
          NT$5.6M
          Net income (H1, 2025)
          (NT$75.0M)
          Cash (H1, 2025)
          NT$131.3M
          EBIT (H1, 2025)
          (NT$79.2M)
          Enterprise value
          $3.1B

          Footer menu